Media

Bio-Path is developing RNAi nanoparticle drugs for some of the most lethal blood cancers and solid tumors. The company’s anticancer drug candidates target the expression of proteins that have been implicated in cancer cell growth and resistance to chemotherapy. Inhibition of these proteins may prove to be a low-toxicity approach to treating patients who would not historically be eligible for anticancer therapies because of their age or other comorbidities or whose cancers are unresponsive to standard treatment approaches. For more information on prexigebersen (Liposomal Grb2), our lead candidate in clinical testing for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), or our other candidates, please refer to our Pipeline.

For media Inquiries
media@biopathholdings.com

Presentations & Publications

View Our Publications